Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Fuda Pharmaceutical Co., Ltd. was a pharmaceutical manufacturing subsidiary of the Shanghai Pharmaceuticals Holding (SPH) group, primarily operating under SPH Sine Pharmaceutical Laboratories. Founded in 1994 and based in Shanghai's Fengxian District, the company specialized in the production of essential chemical drugs and formulations. Its product portfolio included anticoagulants like Warfarin Sodium, aminoglycoside antibiotics such as Amikacin Sulfate, and treatments for Parkinson's disease like Carbidopa. Additionally, the company served as a manufacturing partner for its affiliate, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical, producing specialized therapies such as recombinant human parathyroid hormone (rhPTH) for osteoporosis. In 2024, as part of a strategic restructuring and industrial optimization by SPH, the company officially ceased its operational activities.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai Fuda Pharmaceutical.